Range Impact (RNGE) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-53832
Entity Registrant Name	MALACHITE INNOVATIONS, INC.
Entity Central Index Key	0001438943
Entity Tax Identification Number	75-3268988
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	200 Park Avenue
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Cleveland
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44122
City Area Code	(216)
Local Phone Number	304-6556
Title of 12(b) Security	Common Stock
Trading Symbol	MLCT
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		89,690,149

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 1,026,286	$ 442,369
Accounts receivable	2,897,234	981,385
Unbilled receivables	49,148
Prepaid expenses	103,082	884
Total current assets	4,075,750	1,424,638
Long-term Assets
Property, plant and equipment, net	12,465,584	6,045,514
Land	1,531,758
Goodwill	751,421	751,421
Deposits	19,976	8,892
Total long-term assets	14,768,739	6,805,827
Total Assets	18,844,489	8,230,465
Current Liabilities
Accounts payable	924,282	233,808
Current portion of long-term debt	2,511,380	1,319,201
Line of credit	1,900,000
Total current liabilities	5,335,662	1,553,009
Long-term Liabilities
Long-term debt, net of current portion	5,891,557	3,738,013
Total long-term debt	5,891,557	3,738,013
Total liabilities	11,227,219	5,291,022
Stockholders’ Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 87,516,815 and 78,116,814 shares issued and outstanding, respectively	87,517	78,117
Additional paid-in-capital	54,528,530	53,074,180
Accumulated deficit	(46,998,777)	(50,212,854)
Total stockholders’ equity	7,617,270	2,939,443
Total Liabilities and Stockholders’ Equity	18,844,489	8,230,465
Equipment [Member]
Long-term Assets
Property, plant and equipment, net	12,268,855	6,045,514
Building [Member]
Long-term Assets
Property, plant and equipment, net	$ 196,729

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	87,516,815	78,116,814
Common stock, shares outstanding	87,516,815	78,116,814

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues	$ 5,455,633	$ 1,547,258	$ 12,468,787	$ 2,186,617
Cost of services	2,597,867	1,189,475	8,116,918	1,763,882
Gross profit	2,857,766	357,783	4,351,869	422,735
Operating expenses:
General and administrative	1,057,055	449,041	2,419,001	1,147,308
Research and development	140,840	106,744	354,461	340,297
Total operating expenses	1,197,895	555,785	2,773,462	1,487,605
Income (loss) from operations	1,659,871	(198,002)	1,578,407	(1,064,870)
Other income:
Gain on bargain purchase	1,875,150		1,875,150
Interest expense	(135,467)	(31,049)	(244,101)	(55,341)
Interest income	4,621		4,621
Gain on loan forgiveness		109,435		109,435
Total other income, net	1,744,304	78,386	1,635,670	54,094
Net income (loss)	$ 3,404,175	$ (119,616)	$ 3,214,077	$ (1,010,776)
Income (loss) per common share, basic	$ 0.04	$ 0	$ 0.04	$ (0.02)
Income (loss) per common share, diluted	$ 0.04	$ 0	$ 0.04	$ (0.02)
Weighted average number of common shares outstanding, basic	83,531,308	77,084,205	80,742,455	64,740,745
Weighted average number of common shares outstanding, diluted	83,531,308	77,084,205	80,742,455	64,740,745

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 51,450	$ 48,707,587	$ (49,140,678)	$ (381,641)
Balance, shares at Dec. 31, 2021	51,450,147
Shares issued for cash	$ 21,667	3,228,333		3,250,000
Shares issued for cash, shares	21,666,667
Net income ( loss)			(1,010,776)	(1,010,776)
Shares issued in exchange for Range	$ 5,000	745,000		750,000
Shares issued in exchange for Range, shares	5,000,000
Balance at Sep. 30, 2022	$ 78,117	52,680,920	(50,151,454)	2,607,583
Balance, shares at Sep. 30, 2022	78,116,814
Balance at Jun. 30, 2022	$ 76,450	52,432,587	(50,031,838)	2,477,199
Balance, shares at Jun. 30, 2022	76,450,147
Shares issued for cash	$ 1,667	248,333		250,000
Shares issued for cash, shares	1,666,667
Net income ( loss)			(119,616)	(119,616)
Balance at Sep. 30, 2022	$ 78,117	52,680,920	(50,151,454)	2,607,583
Balance, shares at Sep. 30, 2022	78,116,814
Balance at Dec. 31, 2022	$ 78,117	53,074,180	(50,212,854)	2,939,443
Balance, shares at Dec. 31, 2022	78,116,814
Shares issued for cash	$ 9,400	1,400,600		1,410,000
Shares issued for cash, shares	9,400,001
Fair value of vested stock options		53,750		53,750
Net income ( loss)			3,214,077	3,214,077
Balance at Sep. 30, 2023	$ 87,517	54,528,530	(46,998,777)	7,617,270
Balance, shares at Sep. 30, 2023	87,516,815
Balance at Jun. 30, 2023	$ 80,850	53,517,367	(50,402,952)	3,195,265
Balance, shares at Jun. 30, 2023	80,850,148
Shares issued for cash	$ 6,667	993,333		1,000,000
Shares issued for cash, shares	6,666,667
Fair value of vested stock options		17,830		17,830
Net income ( loss)			3,404,175	3,404,175
Balance at Sep. 30, 2023	$ 87,517	$ 54,528,530	$ (46,998,777)	$ 7,617,270
Balance, shares at Sep. 30, 2023	87,516,815

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 3,404,175	$ (119,616)	$ 3,214,077	$ (1,010,776)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on bargain purchase	(1,875,150)		(1,875,150)
Fair value of vested stock options			53,750
Depreciation	373,935		1,069,845	187,923	$ 395,543
Changes in operating assets and liabilities:
Accounts receivable			(1,915,848)	554,181
Unbilled receivables			(49,148)	(161,263)
Forgiveness of PPP loan				(109,435)
Prepaid expense and other current assets			(102,198)	3,000
Accounts payable and accrued liabilities			690,475	(31,966)
Deposits			(11,084)	(200)
Net cash provided by (used in) operating activities			1,074,719	(568,536)
Cash flows from investing activities:
Equipment purchases			(1,134,417)	(1,243,329)
Cash paid in consideration for Collins Building acquisition			(1,000,000)
Long-term debt issued for Collins Building acquisition			(4,035,250)
Cash paid for acquisition of land			(976,858)
Cash acquired in acquisition of Range Environmental Resources				15,827
Cash paid for acquisition of Range Environmental Resources				(750,000)
Net cash used in investing activities			(7,146,525)	(1,977,502)
Cash flows from financing activities:
Issuance of shares for cash			1,410,000	3,250,000
Proceeds from notes issued in acquisition of Collins Building			4,035,250
Proceeds from long-term debt			383,202	923,309
Repayment of long-term debt			(1,072,729)	(158,815)
Proceeds from (payoff of) line of credit			1,900,000	(350,000)
Net cash provided by financing activities			6,655,723	3,664,494
Net increase in cash and cash equivalents			583,917	1,118,456
Cash and cash equivalents – beginning of period			442,369	38,343	38,343
Cash and cash equivalents – end of period	$ 1,026,286	$ 1,156,799	1,026,286	1,156,799	$ 442,369
Cash paid during the period for:
Interest			244,101	55,341
Forgiveness of PPP loan				109,435
Stock issued for acquisition				750,000
Income taxes

BUSINESS OPERATIONS AND SUMMARY

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Malachite Innovations, Inc. (the “Company”, “we”, “us”, “our” or “Malachite”), was incorporated in the State of Nevada on June 29, 2007. Malachite is a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates several complementary operating businesses focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for our shareholders. Originally founded in 2007 as Legend Mining Inc., the Company began operations as a mineral extraction exploration business focused on Canadian gold reserves, but failed to secure any mineral reserves to execute its strategy. In 2011, the Company changed its name to Stevia First Corp., relocated its operations to California, and pursued a new strategy focused on developing stevia-based sweetener additives for the food and beverage industry by using a novel glycosylation process it developed to chemically attach glucose molecules to stevia molecules. In 2015, due a lack of commercial viability of its glycosylated stevia product, the Company changed its name to Vitality Biopharma, Inc. and used the same glycosylation process to develop non-psychoactive glycosylated cannabinoids for the treatment of chronic inflammatory conditions of the gastrointestinal tract. In October 2021, the Company changed its name to Malachite Innovations, Inc. and created two wholly-owned operating subsidiaries: (i) Graphium Biosciences, Inc., a Nevada corporation (“Graphium”), into which the Company contributed all of its drug development assets; and (ii) Daedalus Ecosciences, Inc., a Nevada corporation (“Daedalus”) which was formed to serve as a holding company for the Company’s future impact investing operating businesses. I n May 2022, Daedalus acquired Range Environmental Resources, Inc., a West Virginia corporation (“Range Environmental”), and Range Natural Resources, Inc., a West Virginia corporation (“Range Natural” and together with Range Environmental, the “Range Reclamation Entities”). The Range Reclamation Entities provide land reclamation, water restoration and environmental consulting services to mining and non-mining customers throughout the Appalachian region with the goal of returning land to pre-mining conditions or repurposing the land for natural, commercial, agricultural or recreational use. The Range Reclamation Entities’ water restoration services seek to improve rivers, streams and discharges through novel and innovative treatment applications to help customers meet their various regulatory standards and requirements. The Range Reclamation Entities also provide environmental consulting services to customers typically in connection with land reclamation and water restoration projects and as an additional value-add service, sells water treatment chemicals manufactured by third parties to their customers. Range Natural also provides resource mining services for customers incidental to the reclamation and repurposing of mine sites. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the nine months ended September 30, 2023, the Company recorded net income of $ 3,214,077 1,074,719 The ability to continue as a going concern is dependent on the Company maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company estimates, as of September 30, 2023, that it has sufficient funds to operate the business for 12 months given its cash balance of $ 1,026,286 100,000 Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers”. The core principle of the revenue standard is that a company should recognize revenue by analyzing the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company primarily invoices customers and recognizes revenue on a periodic basis for equipment and labor hours provided to a customer on a particular job based on an agreed-upon hourly rate sheet or a fixed amount for a project. The Company also invoices customers and recognizes revenue for equipment mobilization fees and materials and supplies required to complete a project. The Company invoices for the sales of chemicals, stone and other products and recognizes revenue when the products are delivered to the customer’s designated site or when control of these products is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products. Sales and other taxes that the Company collects concurrent with revenue producing activities are excluded from revenue. Costs for equipment, labor and chemicals are generally expensed as incurred since the projects are generally short-term and not subject to a contract. The Company also invoices customers for the provision of environmental security services on an agreed-upon hourly rate for each project. All revenue is recognized at a point in time. The Company recognizes revenue from contracts for financial reporting purposes over time. Progress toward completion of the Company’s contracts is measured by the percentage of cost incurred to date compared to estimated total costs for each contract. This method is used because management considers total cost to be the best available measure of progress on contracts. Because of inherent uncertainties in estimating costs, it is at least reasonably possible that the estimates used will change significantly within the near term. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. Accounts Receivable Trade accounts receivable are stated at the amount management expects to collect from the balances outstanding at the end of each fiscal period reflected in the consolidated balance sheets. Based on management’s assessment, it has concluded that losses on balances outstanding as of those dates will be immaterial and, therefore, no 2,897,234 981,385 No no Unbilled Receivables Unbilled receivables represent revenue that has been recognized on projects for which billings have not been presented to the customer because the amounts were earned but not billable at the balance sheet date. Property and Equipment Property and equipment is carried at cost. Expenditures for maintenance and repairs are charged to cost of services. Additions and betterments are capitalized. The cost and related accumulated depreciation of equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is reflected in the current year’s earnings. SCHEDULE OF EQUIPMENT September 30, 2023 December 31, 2022 Equipment $ 13,926,936 $ 6,637,814 Buildings 199,500 - Property and equipment, gross 199,500 - Accumulated depreciation (1,660,852 ) (592,300 ) Net book value 12,465,584 6,045,514 Depreciation expense $ 1,069,845 $ 395,543 The Company provides for depreciation of property and equipment using the straight-line method for both financial reporting and federal income tax purposes over the estimated six The Company assesses the recoverability of its property and equipment by determining whether the depreciation of the assets over their remaining lives can be recovered through projected future cash flows generated by the assets. There were no assets identified for impairment. Land Land is carried at cost. The Company assesses the recoverability of its land by determining whether the cost of the land can be recovered through projected future cash flows generated by the land. No land was identified for impairment. Delivery Costs Delivery costs are classified as cost of sales. Goodwill Goodwill is tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not (i.e., a likelihood greater than 50%) that the intangible asset is impaired. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. As of September 30, 2023, the Company had no material lease commitments. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Consolidated Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Basic and Diluted Income (Loss) Per Share Basic income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted income (loss) per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted income (loss) per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 December 31, 2022 Options 9,862,544 9,392,544 Warrants 25,046,669 22,313,335 Total 34,909,213 31,705,879 Anti-dilutive loss per share 34,909,213 31,705,879 Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred. Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s glycosylated cannabinoid drug candidates. Research and development costs are expensed as incurred. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments” requires that the Company disclose estimated fair values of financial instruments. Financial instruments held by the Company include, among others, accounts receivable, accounts payable and long-term debt. The carrying amounts reported in the balance sheets for assets and liabilities qualifying as financial instruments are a reasonable estimate of fair value. Segments As of September 30, 2023, the Company has five which report the operating results of the Range Reclaim segment, which provides land reclamation, water restoration and incidental mining to mining and non-mining customers throughout Appalachia In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; geographic location of operation; nature of products and services; and procurement, manufacturing, and distribution processes. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

ACQUISITION OF COLLINS BUILDING

ACQUISITION OF COLLINS BUILDING & CONTRACTING	9 Months Ended
	Sep. 30, 2023
Collins Building and Contracting [Member]
Business Acquisition [Line Items]
ACQUISITION OF COLLINS BUILDING & CONTRACTING	2. ACQUISITION OF COLLINS BUILDING & CONTRACTING On August 31, 2023, the Company entered into a stock purchase agreement with the owner of Collins Building & Contracting, Inc. (“Collins Building”), pursuant to which the owner agreed to sell all of the outstanding common stock of Collins Building to the Company in exchange for (a) cash consideration of $1,000,000, (b) a five-year secured promissory note in the principal amount of $2,000,000, bearing interest at 7.0% per annum (the “First Promissory Note”), and (c) a two-year secured promissory note in the principal amount of $2,035,250, bearing interest at 8.25% per annum (the “Second Promissory Note”). The Company accounted for the transaction as a business combination in accordance ASC 805 “Business Combinations”. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed. The fair values of the assets acquired are set forth below. Because the fair values exceeded the purchase price, we recognized a gain on the purchase of $ 1,875,150 SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE Fair value of assets acquired: Equipment $ 6,156,000 Land 554,900 Buildings 199,500 Total assets acquired 6,910,400 Less: Gain on bargain purchase price (1,875,150 ) Purchase price $ 5,035,250 Cash consideration 1,000,000 Long-term notes issued to the seller 4,035,250 Total purchase price $ 5,035,250 Acquisition transaction costs incurred $ 167,212

ACQUISITION OF RANGE ENVIRONMEN

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES	9 Months Ended
	Sep. 30, 2023
Range Reclamation Entities [Member]
Business Acquisition [Line Items]
ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES	3. ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES In May 2022, the Company and its wholly-owned subsidiary, Daedalus Ecosciences, Inc., entered into a share purchase agreement with Range Environmental Resources, Inc. (“Range Environmental”) and Range Natural Resources, Inc. (“Range Natural”, and collectively with Range Environmental, the “Range Reclamation Entities”), and the two (2) shareholders of the Range Reclamation Entities (the “Range Shareholders”) (the “Range Share Purchase Agreement”), pursuant to which the Company issued a total of 10,000,000 1,000,000 80 Subsequent to entering into the Range Share Purchase Agreement, the Company discovered that Joshua Justice, one of the Range Shareholders (“Justice”), made certain misrepresentations in the Range Share Purchase Agreement. On July 12, 2022, the Company entered into a Separation Agreement, by and among the Company, Daedalus Ecosciences, the Range Reclamation Entities, and Justice and his spouse (the “Separation Agreement”) pursuant to which Justice: a) acknowledged that his employment with the Range Reclamation Entities was terminated for cause effective June 30, 2022; b) returned the 5,000,000 shares of the Company’s common stock that had been issued to him under the terms of the Range Share Purchase Agreement; c) transferred his 10% interest in each of the Range Reclamation Entities to Daedalus Ecosciences; and d) paid cash in an amount of $250,000. As a result, only 5,000,000 of the Company’s common stock issued to the Range Shareholders is considered to have been issued in exchange for 90% of the outstanding common stock of each of the Range Reclamation Entities. Subsequently, on October 11, 2022, Daedalus Ecosciences and Jeremy Starks, the remaining Range Shareholder (“Starks”), entered into a share purchase agreement, effective as of May 11, 2022 (the “Starks Agreement”), pursuant to which Starks exchanged his 10 10 Range The Company accounted for the above transactions as a business combination in accordance ASC 805 “Business Combinations”. The Company has performed an allocation of the purchase price paid for the assets acquired and the liabilities assumed. The fair values of the assets acquired are set forth below. The allocation of the purchase price is based on management’s estimates. SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE Fair value of assets acquired: Cash $ 15,827 Accounts receivables 889,919 Property and equipment 628,000 Goodwill 751,421 Total assets acquired 2,285,167 Fair value of liabilities assumed (785,167 ) Purchase price $ 1,500,000 Cash consideration 750,000 Common stock consideration 750,000 Total purchase price $ 1,500,000 Acquisition transaction costs incurred $ 20,592 Goodwill has an assigned value of $ 751,421 value of the Range Reclamation Entities’ brand reputation, customer base and employee relations.

GOODWILL

GOODWILL	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL	4. GOODWILL Goodwill was $ 751,421 value of the Range Reclamation Entities’ employee relations SCHEDULE OF GOODWILL September 30, 2023 December 31, 2022 Environmental Services: Beginning Balance $ 751,421 $ - Acquisitions - 751,421 Adjustments - - Ending Balance $ 751,421 $ 751,421

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
EQUITY	5. EQUITY Issuance of Common Stock and Warrants On April 11, 2023, the Company entered into securities purchase agreements providing for the issuance and sale by the Company of (i) 2,733,334 0.15 2,733,333 0.60 400,000 On August 24, 2023, the Company entered into a securities purchase agreement providing for the issuance and sale by the Company of 6,666,667 1,000,000

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS	6. STOCK OPTIONS Stock options issued during the three months ended September 30, 2023 and the three months ended September 30, 2022 During the three months ended September 30, 2023, the Company granted options to an outside advisor to purchase 100,000 0.1337 100,000 273.24 4.27 zero 5 13,340 No During the three months ended September 30, 2023, total stock-based compensation expense related to vested stock options was $ 17,830 31,430 2 A summary of the Company’s stock option activity during the nine months ended September 30, 2023 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at December 31, 2022 9,392,544 $ 0.54 Granted 500,000 0.17 Exchanged - - Exercised - - Expired (30,000 ) 3.50 Forfeited - - Balance outstanding at September 30, 2023 9,862,544 $ 0.51 Balance exercisable at September 30, 2023 9,662,544 $ 0.52 At September 30, 2023, the 9,862,544 2,630 A summary of the Company’s stock options outstanding as of September 30, 2023 is as follows: SCHEDULE OF STOCK OPTION OUTSTANDING Number of Options Weighted Average Exercise Price Weighted Average Grant- Date Stock Price Options Outstanding, September 30, 2023 100,000 $ 0.1337 $ 0.1337 3,050,000 $ 0.18 $ 0.18 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 350,834 $ 1.50 1.95 $ 1.50 1.95 597,500 $ 2.00 2.79 $ 2.00 2.79 53,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 9,862,544 A summary of the Company’s stock options outstanding and exercisable as of September 30, 2023 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Number of Options Weighted Average Exercise Price Weighted Average Grant- Date Stock Price Options Outstanding and Exercisable, September 30, 2023 100,000 $ 0.1337 $ 0.1337 2,850,000 $ 0.18 $ 0.18 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 350,834 $ 1.50 1.95 $ 1.50 1.95 597,500 $ 2.00 2.79 $ 2.00 2.79 53,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 9,662,544

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2023
Warrants
WARRANTS	7. WARRANTS A summary of warrants to purchase common stock issued during the nine months ended September 30, 2023 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at December 31, 2022 22,313,335 $ 0.61 Granted 2,733,334 0.60 Exercised - - Expired - - Balance outstanding and exercisable at September 30, 2023 25,046,669 $ 0.61 At September 30, 2023, the 25,046,669 no

LINES OF CREDIT

LINES OF CREDIT	9 Months Ended
	Sep. 30, 2023
Lines Of Credit
LINES OF CREDIT	8. LINES OF CREDIT In November 2022, the Company secured a bank line of credit with a limit of $ 1,000,000 November 30, 2023 1 9.50 1,000,000 In June 2023, the Range Reclamation Entities secured a separate bank line of credit with a limit of $ 1,000,000 June 24, 2024 8.50 900,000

LONG-TERM DEBT OBLIGATIONS

LONG-TERM DEBT OBLIGATIONS	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
LONG-TERM DEBT OBLIGATIONS	9. LONG-TERM DEBT OBLIGATIONS Long-term debt consists of debt on vehicles and equipment, which serves as the collateral, and debt issued as part of the acquisition of Collins Building. Interest rates range from 3.69 9.95 The debt matures from 2023 through 2028. A summary of payments due under the long-term debt by year is as follows: SCHEDULE OF MATURITIES OF LONG TERM DEBT 2023 – due between October 1, 2023 and September 30, 2024 $ 2,511,380 2024 – due between October 1, 2024 and September 30, 2025 2,393,306 2025 – due between October 1, 2025 and September 30, 2026 1,193,289 2026 – due between October 1, 2026 and September 30, 2027 1,214,323 2027 – due between October 1, 2027 and September 30, 2028 1,024,390 2028 and later – due on October 1, 2028 and thereafter 66,249 Total long-term debt $ 8,402,937

MAJOR CUSTOMER AND CONCENTRATIO

MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK	9 Months Ended
	Sep. 30, 2023
Risks and Uncertainties [Abstract]
MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK	10. MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK Sales to the Company’s two largest customers were 95 93 74 73 Accounts receivable from one customer were 96 61

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES The Company received a letter in February 2021 from counsel for the Company’s director’s and officer’s insurance carrier (the “insurer”) demanding that the Company reimburse the insurer for sums advanced by the insurer to a former director of the Company as defense costs in connection with a claim purportedly arising under a previous directors and officers insurance policy. The Company believes it has no liability for this claim on the basis of, among other things, Nevada law, the Company’s governing documents and the language of the policy. Accordingly, as of September 30, 2023, no contingent liability has been recorded in the Company’s consolidated statements of financial condition for this matter.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	12. SEGMENT INFORMATION ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services, categories, business segments and major customers in financial statements. The Company has five The five reportable segments that result from applying the aggregation criteria are as follows: ● Range Reclaim – land reclamation, water restoration , incidental mining and land repurposing ● Range Water - biochar product development and water solutions business ● Range Security – security services on mine land being reclaimed and repurposed for non-fossil fuel uses ● Range Land – mine land being acquired, reclaimed and repurposed for non-fossil fuel uses ● Drug Development – glycosylated cannabinoid drug development program The Company operated two reportable business segments during the three and nine months ended September 30, 2022, the Drug Development and Range Reclaim segments. The other business segments began operating in 2023. The Company had no inter-segment sales for the periods presented. Summarized financial information concerning the Company’s reportable segments is shown as below: SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT By Categories For the three months ended September 30, 2023 Range Reclaim Range Water Range Security Range Land Drug Development Corporate Total Sales $ 5,299,415 $ - $      156,218 $ - $ - $ - $ 5,455,633 Cost of services 2,514,503 - 83,364 - - - 2,597,867 Gross profit 2,784,912 - 72,854 - - - 2,857,766 Net income (loss) 4,048,527 (15,376 ) 50,555 - (140,840 ) (538,691 ) 3,404,175 Total assets 17,227,868 14,498 136,835 1,009,988 11,859 443,441 18,844,489 Depreciation 370,404 640 2,891 - - - 373,935 Interest expense 93,933 - - - - 41,534 135,467 Tax expense - - - - - - - Capital expenditures for long-lived assets $ 349,898 $ - $ - $ 976,858 $ - $ - $ 1,326,756 For the nine months ended September 30, 2023 Range Reclaim Range Water Range Security Range Land Drug Development Corporate Total Sales $ 12,170,394 $ - $ 298,393 $ - $ - $ - $ 12,468,787 Cost of services 7,957,216 - 159,702 - - - 8,116,918 Gross profit 4,213,178 - 138,691 - - - 4,351,869 Net income (loss) 4,669,092 (53,656 ) 71,000 - (354,461 ) (1,117,898 ) 3,214,077 Total assets 17,227,868 14,498 136,835 1,009,988 11,859 443,441 18,844,489 Depreciation 1,061,569 1,066 7,210 - - - 1,069,845 Interest expense 199,744 - 224 - - 44,133 244,101 Tax expense - - - - - - - Capital expenditures for long-lived assets $ 1,066,389 $ 15,350 $ 52,674 $ 976,858 $ - $ - $ 2,111,271 For the three months ended September 30, 2022 Range Reclaim Drug Development Corporate Total Revenue $ 1,547,258 $ - $ - $ 1,547,258 Cost of services 1,189,475 - - 1,189,475 Gross profit 357,783 - - 357,783 Net income (loss) 213,865 (106,744 ) (226,737 ) (119,616 ) Total assets 3,518,019 8,334 681,298 4,207,651 Capital expenditures for long-lived assets $ 135,495 $ - $ - $ 135,495 For the nine months ended September 30, 2022 Range Reclaim Drug Development Corporate Total Revenue $ 2,186,617 $ - $ - $ 2,186,617 Cost of services 1,763,882 - - 1,763,882 Gross profit 422,735 - - 422,735 Net income (loss) 153,719 (340,297 ) (824,198 ) (1,010,776 ) Total assets 3,518,019 8,334 681,298 4,207,651 Capital expenditures for long-lived assets $ 1,243,328 $ - $ - $ 1,243,328

PRO FORMA INFORMATION

PRO FORMA INFORMATION	9 Months Ended
	Sep. 30, 2023
Pro Forma Information
PRO FORMA INFORMATION	13. PRO FORMA INFORMATION The unaudited pro forma sales and net income data gives effect to the acquisition of Collins Building as if it had occurred on January 1, 2023, the beginning of the Company’s 2023 fiscal year, and to the acquisition of the Range Entities as if it had occurred on January 1, 2022, the beginning of the Company’s 2022 fiscal year. SCHEDULE OF PRO FORMA DATA INFORMATION For the nine months ended Sales Net income Acquired companies - - Collins Building $ 1,787,675 $ 2,992,901 All other companies 12,600,670 1,462,527 Total $ 14,388,345 $ 4,455,428 For the nine months ended Sales Net loss Acquired companies - - Range Entities $ 2,186,617 $ (43,266 ) All other companies - (1,071,014 ) Total $ 2,186,617 $ (1,114,280 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS On October 30, 2023, the Company entered into warrant exchange agreements with certain holders of warrants to exchange warrants to purchase a total of 21,733,334 2,173,334

BUSINESS OPERATIONS AND SUMMA_2

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the nine months ended September 30, 2023, the Company recorded net income of $ 3,214,077 1,074,719 The ability to continue as a going concern is dependent on the Company maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company estimates, as of September 30, 2023, that it has sufficient funds to operate the business for 12 months given its cash balance of $ 1,026,286 100,000
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers”. The core principle of the revenue standard is that a company should recognize revenue by analyzing the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company primarily invoices customers and recognizes revenue on a periodic basis for equipment and labor hours provided to a customer on a particular job based on an agreed-upon hourly rate sheet or a fixed amount for a project. The Company also invoices customers and recognizes revenue for equipment mobilization fees and materials and supplies required to complete a project. The Company invoices for the sales of chemicals, stone and other products and recognizes revenue when the products are delivered to the customer’s designated site or when control of these products is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products. Sales and other taxes that the Company collects concurrent with revenue producing activities are excluded from revenue. Costs for equipment, labor and chemicals are generally expensed as incurred since the projects are generally short-term and not subject to a contract. The Company also invoices customers for the provision of environmental security services on an agreed-upon hourly rate for each project. All revenue is recognized at a point in time. The Company recognizes revenue from contracts for financial reporting purposes over time. Progress toward completion of the Company’s contracts is measured by the percentage of cost incurred to date compared to estimated total costs for each contract. This method is used because management considers total cost to be the best available measure of progress on contracts. Because of inherent uncertainties in estimating costs, it is at least reasonably possible that the estimates used will change significantly within the near term.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.
Accounts Receivable	Accounts Receivable Trade accounts receivable are stated at the amount management expects to collect from the balances outstanding at the end of each fiscal period reflected in the consolidated balance sheets. Based on management’s assessment, it has concluded that losses on balances outstanding as of those dates will be immaterial and, therefore, no 2,897,234 981,385 No no
Unbilled Receivables	Unbilled Receivables Unbilled receivables represent revenue that has been recognized on projects for which billings have not been presented to the customer because the amounts were earned but not billable at the balance sheet date.
Property and Equipment	Property and Equipment Property and equipment is carried at cost. Expenditures for maintenance and repairs are charged to cost of services. Additions and betterments are capitalized. The cost and related accumulated depreciation of equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is reflected in the current year’s earnings. SCHEDULE OF EQUIPMENT September 30, 2023 December 31, 2022 Equipment $ 13,926,936 $ 6,637,814 Buildings 199,500 - Property and equipment, gross 199,500 - Accumulated depreciation (1,660,852 ) (592,300 ) Net book value 12,465,584 6,045,514 Depreciation expense $ 1,069,845 $ 395,543 The Company provides for depreciation of property and equipment using the straight-line method for both financial reporting and federal income tax purposes over the estimated six The Company assesses the recoverability of its property and equipment by determining whether the depreciation of the assets over their remaining lives can be recovered through projected future cash flows generated by the assets. There were no assets identified for impairment.
Land	Land Land is carried at cost. The Company assesses the recoverability of its land by determining whether the cost of the land can be recovered through projected future cash flows generated by the land. No land was identified for impairment.
Delivery Costs	Delivery Costs Delivery costs are classified as cost of sales.
Goodwill	Goodwill Goodwill is tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not (i.e., a likelihood greater than 50%) that the intangible asset is impaired.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Leases	Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. As of September 30, 2023, the Company had no material lease commitments.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Consolidated Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share Basic income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted income (loss) per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted income (loss) per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 December 31, 2022 Options 9,862,544 9,392,544 Warrants 25,046,669 22,313,335 Total 34,909,213 31,705,879 Anti-dilutive loss per share 34,909,213 31,705,879
Patents and Patent Application Costs	Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Accordingly, patent costs are expensed as incurred.
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s glycosylated cannabinoid drug candidates. Research and development costs are expensed as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments” requires that the Company disclose estimated fair values of financial instruments. Financial instruments held by the Company include, among others, accounts receivable, accounts payable and long-term debt. The carrying amounts reported in the balance sheets for assets and liabilities qualifying as financial instruments are a reasonable estimate of fair value.
Segments	Segments As of September 30, 2023, the Company has five which report the operating results of the Range Reclaim segment, which provides land reclamation, water restoration and incidental mining to mining and non-mining customers throughout Appalachia In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; geographic location of operation; nature of products and services; and procurement, manufacturing, and distribution processes.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

BUSINESS OPERATIONS AND SUMMA_3

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF EQUIPMENT	SCHEDULE OF EQUIPMENT September 30, 2023 December 31, 2022 Equipment $ 13,926,936 $ 6,637,814 Buildings 199,500 - Property and equipment, gross 199,500 - Accumulated depreciation (1,660,852 ) (592,300 ) Net book value 12,465,584 6,045,514 Depreciation expense $ 1,069,845 $ 395,543
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 December 31, 2022 Options 9,862,544 9,392,544 Warrants 25,046,669 22,313,335 Total 34,909,213 31,705,879 Anti-dilutive loss per share 34,909,213 31,705,879

ACQUISITION OF COLLINS BUILDI_2

ACQUISITION OF COLLINS BUILDING & CONTRACTING (Tables)	9 Months Ended
	Sep. 30, 2023
Collins Building and Contracting [Member]
Business Acquisition [Line Items]
SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE	SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE Fair value of assets acquired: Equipment $ 6,156,000 Land 554,900 Buildings 199,500 Total assets acquired 6,910,400 Less: Gain on bargain purchase price (1,875,150 ) Purchase price $ 5,035,250 Cash consideration 1,000,000 Long-term notes issued to the seller 4,035,250 Total purchase price $ 5,035,250 Acquisition transaction costs incurred $ 167,212

ACQUISITION OF RANGE ENVIRONM_2

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES (Tables)	9 Months Ended
	Sep. 30, 2023
Range Reclamation Entities [Member]
Business Acquisition [Line Items]
SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE	SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE Fair value of assets acquired: Cash $ 15,827 Accounts receivables 889,919 Property and equipment 628,000 Goodwill 751,421 Total assets acquired 2,285,167 Fair value of liabilities assumed (785,167 ) Purchase price $ 1,500,000 Cash consideration 750,000 Common stock consideration 750,000 Total purchase price $ 1,500,000 Acquisition transaction costs incurred $ 20,592

GOODWILL (Tables)

GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF GOODWILL	SCHEDULE OF GOODWILL September 30, 2023 December 31, 2022 Environmental Services: Beginning Balance $ 751,421 $ - Acquisitions - 751,421 Adjustments - - Ending Balance $ 751,421 $ 751,421

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SUMMARY OF STOCK OPTION ACTIVITY	A summary of the Company’s stock option activity during the nine months ended September 30, 2023 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at December 31, 2022 9,392,544 $ 0.54 Granted 500,000 0.17 Exchanged - - Exercised - - Expired (30,000 ) 3.50 Forfeited - - Balance outstanding at September 30, 2023 9,862,544 $ 0.51 Balance exercisable at September 30, 2023 9,662,544 $ 0.52
SCHEDULE OF STOCK OPTION OUTSTANDING	A summary of the Company’s stock options outstanding as of September 30, 2023 is as follows: SCHEDULE OF STOCK OPTION OUTSTANDING Number of Options Weighted Average Exercise Price Weighted Average Grant- Date Stock Price Options Outstanding, September 30, 2023 100,000 $ 0.1337 $ 0.1337 3,050,000 $ 0.18 $ 0.18 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 350,834 $ 1.50 1.95 $ 1.50 1.95 597,500 $ 2.00 2.79 $ 2.00 2.79 53,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 9,862,544
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE	A summary of the Company’s stock options outstanding and exercisable as of September 30, 2023 is as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Number of Options Weighted Average Exercise Price Weighted Average Grant- Date Stock Price Options Outstanding and Exercisable, September 30, 2023 100,000 $ 0.1337 $ 0.1337 2,850,000 $ 0.18 $ 0.18 1,150,000 $ 0.277 $ 0.277 750,000 $ 0.30 $ 0.30 2,000,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 350,834 $ 1.50 1.95 $ 1.50 1.95 597,500 $ 2.00 2.79 $ 2.00 2.79 53,334 $ 3.10 3.80 $ 3.10 3.80 18,334 $ 4.00 4.70 $ 4.00 4.70 9,662,544

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2023
Warrants
SCHEDULE OF WARRANTS ACTIVITY	A summary of warrants to purchase common stock issued during the nine months ended September 30, 2023 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Average Exercise Price Balance outstanding at December 31, 2022 22,313,335 $ 0.61 Granted 2,733,334 0.60 Exercised - - Expired - - Balance outstanding and exercisable at September 30, 2023 25,046,669 $ 0.61 At September 30, 2023, the 25,046,669 no

LONG-TERM DEBT OBLIGATIONS (Tab

LONG-TERM DEBT OBLIGATIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF MATURITIES OF LONG TERM DEBT	A summary of payments due under the long-term debt by year is as follows: SCHEDULE OF MATURITIES OF LONG TERM DEBT 2023 – due between October 1, 2023 and September 30, 2024 $ 2,511,380 2024 – due between October 1, 2024 and September 30, 2025 2,393,306 2025 – due between October 1, 2025 and September 30, 2026 1,193,289 2026 – due between October 1, 2026 and September 30, 2027 1,214,323 2027 – due between October 1, 2027 and September 30, 2028 1,024,390 2028 and later – due on October 1, 2028 and thereafter 66,249 Total long-term debt $ 8,402,937

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT	Summarized financial information concerning the Company’s reportable segments is shown as below: SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT By Categories For the three months ended September 30, 2023 Range Reclaim Range Water Range Security Range Land Drug Development Corporate Total Sales $ 5,299,415 $ - $      156,218 $ - $ - $ - $ 5,455,633 Cost of services 2,514,503 - 83,364 - - - 2,597,867 Gross profit 2,784,912 - 72,854 - - - 2,857,766 Net income (loss) 4,048,527 (15,376 ) 50,555 - (140,840 ) (538,691 ) 3,404,175 Total assets 17,227,868 14,498 136,835 1,009,988 11,859 443,441 18,844,489 Depreciation 370,404 640 2,891 - - - 373,935 Interest expense 93,933 - - - - 41,534 135,467 Tax expense - - - - - - - Capital expenditures for long-lived assets $ 349,898 $ - $ - $ 976,858 $ - $ - $ 1,326,756 For the nine months ended September 30, 2023 Range Reclaim Range Water Range Security Range Land Drug Development Corporate Total Sales $ 12,170,394 $ - $ 298,393 $ - $ - $ - $ 12,468,787 Cost of services 7,957,216 - 159,702 - - - 8,116,918 Gross profit 4,213,178 - 138,691 - - - 4,351,869 Net income (loss) 4,669,092 (53,656 ) 71,000 - (354,461 ) (1,117,898 ) 3,214,077 Total assets 17,227,868 14,498 136,835 1,009,988 11,859 443,441 18,844,489 Depreciation 1,061,569 1,066 7,210 - - - 1,069,845 Interest expense 199,744 - 224 - - 44,133 244,101 Tax expense - - - - - - - Capital expenditures for long-lived assets $ 1,066,389 $ 15,350 $ 52,674 $ 976,858 $ - $ - $ 2,111,271 For the three months ended September 30, 2022 Range Reclaim Drug Development Corporate Total Revenue $ 1,547,258 $ - $ - $ 1,547,258 Cost of services 1,189,475 - - 1,189,475 Gross profit 357,783 - - 357,783 Net income (loss) 213,865 (106,744 ) (226,737 ) (119,616 ) Total assets 3,518,019 8,334 681,298 4,207,651 Capital expenditures for long-lived assets $ 135,495 $ - $ - $ 135,495 For the nine months ended September 30, 2022 Range Reclaim Drug Development Corporate Total Revenue $ 2,186,617 $ - $ - $ 2,186,617 Cost of services 1,763,882 - - 1,763,882 Gross profit 422,735 - - 422,735 Net income (loss) 153,719 (340,297 ) (824,198 ) (1,010,776 ) Total assets 3,518,019 8,334 681,298 4,207,651 Capital expenditures for long-lived assets $ 1,243,328 $ - $ - $ 1,243,328

PRO FORMA INFORMATION (Tables)

PRO FORMA INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2023
Pro Forma Information
SCHEDULE OF PRO FORMA DATA INFORMATION	The unaudited pro forma sales and net income data gives effect to the acquisition of Collins Building as if it had occurred on January 1, 2023, the beginning of the Company’s 2023 fiscal year, and to the acquisition of the Range Entities as if it had occurred on January 1, 2022, the beginning of the Company’s 2022 fiscal year. SCHEDULE OF PRO FORMA DATA INFORMATION For the nine months ended Sales Net income Acquired companies - - Collins Building $ 1,787,675 $ 2,992,901 All other companies 12,600,670 1,462,527 Total $ 14,388,345 $ 4,455,428 For the nine months ended Sales Net loss Acquired companies - - Range Entities $ 2,186,617 $ (43,266 ) All other companies - (1,071,014 ) Total $ 2,186,617 $ (1,114,280 )

SCHEDULE OF EQUIPMENT (Details)

SCHEDULE OF EQUIPMENT (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ (1,660,852)	$ (1,660,852)		$ (592,300)
Net book value	12,465,584	12,465,584		6,045,514
Depreciation expense	373,935	1,069,845	$ 187,923	395,543
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13,926,936	13,926,936		6,637,814
Net book value	12,268,855	12,268,855		6,045,514
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	199,500	199,500
Net book value	$ 196,729	$ 196,729

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per share	34,909,213	31,705,879
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per share	9,862,544	9,392,544
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive loss per share	25,046,669	22,313,335

BUSINESS OPERATIONS AND SUMMA_4

BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Net loss	$ 3,404,175	$ (119,616)	$ 3,214,077	$ (1,010,776)
Cash used in operating activities			$ 1,074,719	(568,536)
Going concern, description			The Company estimates, as of September 30, 2023, that it has sufficient funds to operate the business for 12 months given its cash balance of $1,026,286, line of credit availability of $100,000, and revenues being generated by the Range Reclamation Entities.
Cash and cash equivalents	1,026,286		$ 1,026,286		$ 442,369
Line of credit current borrowing capacity	100,000		100,000
Allowances for doubtful accounts receivable	0	0	0	$ 0	0
Accounts receivable	2,897,234		$ 2,897,234		$ 981,385
Bad debt expense	$ 0	$ 0
Equipment estimated useful lives	6 years		6 years
Number of operating segments | Segment			5

SCHEDULE OF BUSINESS ACQUISITIO

SCHEDULE OF BUSINESS ACQUISITION ALLOCATION OF PURCHASE PRICE (Details) - USD ($)			1 Months Ended
	Aug. 31, 2023	May 31, 2022	Aug. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill				$ 751,421	$ 751,421
Collins Building and Contracting [Member]
Business Acquisition [Line Items]
Equipment	$ 6,156,000		$ 6,156,000
Land	554,900		554,900
Buildings	199,500		199,500
Total assets acquired	6,910,400		6,910,400
Less: Gain on bargain purchase price	(1,875,150)
Purchase price	5,035,250
Cash consideration	1,000,000
Total purchase price	5,035,250
Acquisition transaction costs incurred	167,212		167,212
Fair value of liabilities assumed	$ (1,875,150)		(1,875,150)
Range Reclamation Entities [Member]
Business Acquisition [Line Items]
Total assets acquired		$ 2,285,167
Purchase price		1,500,000
Cash consideration		750,000
Common stock consideration		750,000	$ 4,035,250
Total purchase price		1,500,000
Acquisition transaction costs incurred		20,592
Cash		15,827
Accounts receivables		889,919
Property and equipment		628,000
Goodwill		751,421
Fair value of liabilities assumed		$ (785,167)

ACQUISITION OF COLLINS BUILDI_3

ACQUISITION OF COLLINS BUILDING & CONTRACTING (Details Narrative) - Collins Building and Contracting [Member]	Aug. 31, 2023 USD ($)
Business Acquisition [Line Items]
Gain on the purchase	$ 1,875,150
Separation Agreement [Member]
Business Acquisition [Line Items]
Agreement, description	cash consideration of $1,000,000, (b) a five-year secured promissory note in the principal amount of $2,000,000, bearing interest at 7.0% per annum (the “First Promissory Note”), and (c) a two-year secured promissory note in the principal amount of $2,035,250, bearing interest at 8.25% per annum (the “Second Promissory Note”).

ACQUISITION OF RANGE ENVIRONM_3

ACQUISITION OF RANGE ENVIRONMENTAL RESOURCES AND RANGE NATURAL RESOURCES (Details Narrative) - USD ($)	Jul. 12, 2022	May 31, 2022	Sep. 30, 2023	Dec. 31, 2022	Oct. 11, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill			$ 751,421	$ 751,421
Range Reclamation Entities [Member]
Business Acquisition [Line Items]
Business acquisition, cash consideration		$ 1,500,000
Goodwill		$ 751,421
Share Purchase Agreement [Member] | Range Reclamation Entities [Member]
Business Acquisition [Line Items]
Business acquisition, ownership percentage		80%
Share Purchase Agreement [Member] | Jeremy Starks [Member]
Business Acquisition [Line Items]
Business acquisition, ownership percentage					10%
Contractual profits interest					10%
Share Purchase Agreement [Member] | Range Reclamation Entities [Member]
Business Acquisition [Line Items]
Business acquisition, number of shares issued		10,000,000
Business acquisition, cash consideration		$ 1,000,000
Separation Agreement [Member] | Range Reclamation Entities [Member]
Business Acquisition [Line Items]
Agreement, description	pursuant to which Justice: a) acknowledged that his employment with the Range Reclamation Entities was terminated for cause effective June 30, 2022; b) returned the 5,000,000 shares of the Company’s common stock that had been issued to him under the terms of the Range Share Purchase Agreement; c) transferred his 10% interest in each of the Range Reclamation Entities to Daedalus Ecosciences; and d) paid cash in an amount of $250,000. As a result, only 5,000,000 of the Company’s common stock issued to the Range Shareholders is considered to have been issued in exchange for 90% of the outstanding common stock of each of the Range Reclamation Entities.

SCHEDULE OF GOODWILL (Details)

SCHEDULE OF GOODWILL (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 751,421
Acquisitions		751,421
Adjustments
Ending Balance	$ 751,421	$ 751,421

GOODWILL (Details Narrative)

GOODWILL (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 751,421	$ 751,421

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)			9 Months Ended
	Aug. 24, 2023	Apr. 11, 2023	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of stock and warrants			$ 1,410,000	$ 3,250,000
Two Securities Purchase Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock, shares issued	6,666,667	2,733,334
Sale of stock, price per share		$ 0.15
Warrants issued to purchase stock		2,733,333
Warrant exercise price		$ 0.60
Proceeds from sale of stock and warrants	$ 1,000,000	$ 400,000

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares Outstanding, Balance | shares	9,392,544
Weighted Average Exercise Price, Outstanding Balance | $ / shares	$ 0.54
Shares, Granted | shares	500,000
Weighted Average Exercise Price, Granted | $ / shares	$ 0.17
Shares, Exchanged | shares
Weighted Average Exercise Price, Exchanged | $ / shares
Shares, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Shares, Expired | shares	(30,000)
Weighted Average Exercise Price, Expired | $ / shares	$ 3.50
Shares, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Shares Outstanding, Balance | shares	9,862,544
Weighted Average Exercise Price, Outstanding Balance | $ / shares	$ 0.51
Shares, Balance Exercisable | shares	9,662,544
Weighted Average Exercise Price, Balance Exercisable | $ / shares	$ 0.52

SCHEDULE OF STOCK OPTION OUTSTA

SCHEDULE OF STOCK OPTION OUTSTANDING (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	9,862,544		9,392,544
Weighted Average Exercise Price, Outstanding Balance	$ 0.51		$ 0.54
Weighted Average Exercise Price, Granted	$ 0.17
Stock Options One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	100,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.1337
Weighted Average Exercise Price, Granted	$ 0.1337
Stock Options Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	3,050,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.18
Weighted Average Exercise Price, Granted	$ 0.18
Stock Options Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	1,150,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.277
Weighted Average Exercise Price, Granted	$ 0.277
Stock Options Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	750,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.30
Weighted Average Exercise Price, Granted	$ 0.30
Stock Options Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	2,000,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.35
Weighted Average Exercise Price, Granted	$ 0.35
Stock Options Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	1,664,542
Weighted Average Exercise Price, Outstanding Balance	$ 0.50
Weighted Average Exercise Price, Granted	$ 0.50
Stock Options Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	128,000
Weighted Average Exercise Price, Outstanding Balance	$ 0.96
Stock Options Seven [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Granted	$ 0.96
Stock Options Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	350,834
Stock Options Eight [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 1.50
Weighted Average Exercise Price, Granted	1.50
Stock Options Eight [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	1.95
Weighted Average Exercise Price, Granted	$ 1.95
Stock Options Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	597,500
Stock Options Nine [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 2
Weighted Average Exercise Price, Granted	2
Stock Options Nine [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	2.79
Weighted Average Exercise Price, Granted	$ 2.79
Stock Options Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	53,334
Stock Options Ten [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 3.10
Weighted Average Exercise Price, Granted	3.10
Stock Options Ten [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	3.80
Weighted Average Exercise Price, Granted	$ 3.80
Stock Options Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding balance	18,334
Stock Options Eleven [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance	$ 4
Weighted Average Exercise Price, Granted	4
Stock Options Eleven [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Balance		$ 4.70
Weighted Average Exercise Price, Granted	$ 4.70

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details)	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	9,662,544
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.52
Stock Options One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	100,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.1337
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.1337
Stock Options Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	2,850,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.18
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.18
Stock Options Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	1,150,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.277
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.277
Stock Options Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	750,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.30
Stock Options Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	2,000,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.35
Stock Options Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	1,664,542
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.50
Stock Options Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	128,000
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 0.96
Stock Options Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	350,834
Stock Options Eight [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	1.50
Stock Options Eight [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	1.95
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 1.95
Stock Options Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	597,500
Stock Options Nine [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 2
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	2
Stock Options Nine [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	2.79
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 2.79
Stock Options Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	53,334
Stock Options Ten [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	3.10
Stock Options Ten [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	3.80
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 3.80
Stock Options Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Options Outstanding and exercisable | shares	18,334
Stock Options Eleven [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	$ 4
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	4
Stock Options Eleven [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding and exercisable	4.70
Weighted Average Grant-date Stock Price, Options Outstanding and exercisable	$ 4.70

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price		$ 0.17
Share based compensation arrangement by share based payment award options grants in period gross		500,000
Stock options issued to value		$ 53,750
Stock based compensation expense	$ 17,830
Unamortized cost of outstanding stock-based awards	$ 31,430	$ 31,430
Remaining vesting period	2 years
Stock options outstanding	9,862,544	9,862,544		9,392,544
Stock options, intrinsic value	$ 2,630	$ 2,630
Directors And Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Fair value of the option grants to employees	$ 100,000
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price	$ 0.1337
Share based compensation arrangement by share based payment award options grants in period gross	100,000
Volatility rate	273.24%
Discount rate	4.27%
Expected dividend yield	0%
Expected life	5 years
Stock options issued to value	$ 0
Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Fair value of the option grants to employees	$ 13,340

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares, Warrants Outstanding, Beginning Balance | shares	22,313,335
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance | $ / shares	$ 0.61
Number of Shares, Warrants Granted | shares	2,733,334
Weighted Average Exercise Price, Warrants Outstanding, Granted | $ / shares	$ 0.60
Number of Shares, Warrants Exercised | shares
Weighted Average Exercise Price, Warrants Outstanding, Exercised | $ / shares
Number of Shares, Warrants Expired | shares
Weighted Average Exercise Price, Warrants Outstanding, Expired | $ / shares
Number of Shares, Warrants Outstanding and Exercisable Ending | shares	25,046,669
Weighted Average Exercise Price, Warrants Outstanding, Outstanding and Exercisable, Ending Balance | $ / shares	$ 0.61

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member]	Sep. 30, 2023 USD ($) shares
Warrants outstanding | shares	25,046,669
Warrants intrinsic value | $	$ 0

LINES OF CREDIT (Details Narrat

LINES OF CREDIT (Details Narrative) - USD ($)	1 Months Ended
	Jun. 30, 2023	Nov. 30, 2022	Sep. 30, 2023
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000,000
Line of Credit Facility, Expiration Date		Nov. 30, 2023
Line of Credit Facility, Interest Rate During Period		100%
Long-Term Line of Credit			$ 1,000,000
Secured Debt [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000,000
Line of Credit Facility, Expiration Date	Jun. 24, 2024
Long-Term Line of Credit			$ 900,000
Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			9.50%
Prime Rate [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			8.50%

SCHEDULE OF MATURITIES OF LONG

SCHEDULE OF MATURITIES OF LONG TERM DEBT (Details)	Sep. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2023 – due between October 1, 2023 and September 30, 2024	$ 2,511,380
2024 – due between October 1, 2024 and September 30, 2025	2,393,306
2025 – due between October 1, 2025 and September 30, 2026	1,193,289
2026 – due between October 1, 2026 and September 30, 2027	1,214,323
2027 – due between October 1, 2027 and September 30, 2028	1,024,390
2028 and later – due on October 1, 2028 and thereafter	66,249
Total long-term debt	$ 8,402,937

LONG-TERM DEBT OBLIGATIONS (Det

LONG-TERM DEBT OBLIGATIONS (Details Narrative)	9 Months Ended
	Sep. 30, 2023
Debt Instrument [Line Items]
Long term debt, maturity description	The debt matures from 2023 through 2028.
Minimum [Member]
Debt Instrument [Line Items]
Long term debt, interest rates	3.69%
Maximum [Member]
Debt Instrument [Line Items]
Long term debt, interest rates	9.95%

MAJOR CUSTOMER AND CONCENTRAT_2

MAJOR CUSTOMER AND CONCENTRATION OF CREDIT RISK (Details Narrative) - Customer Concentration Risk [Member] - Largest Customers [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration risk percentage	95%	74%	93%	73%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage			96%	61%

SCHEDULE OF FINANCIAL INFORMATI

SCHEDULE OF FINANCIAL INFORMATION OF REPORTABLE SEGMENT (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 5,455,633	$ 1,547,258	$ 12,468,787	$ 2,186,617
Cost of services	2,597,867	1,189,475	8,116,918	1,763,882
Gross profit	2,857,766	357,783	4,351,869	422,735
Net income (loss)	3,404,175	(119,616)	3,214,077	(1,010,776)
Total assets	18,844,489	4,207,651	18,844,489	4,207,651	$ 8,230,465
Depreciation	373,935		1,069,845	187,923	$ 395,543
Interest expense	135,467	31,049	244,101	55,341
Tax expense
Capital expenditures for long-lived assets	1,326,756	135,495	2,111,271	1,243,328
Range Reclaim [Member]
Segment Reporting Information [Line Items]
Revenue	5,299,415	1,547,258	12,170,394	2,186,617
Cost of services	2,514,503	1,189,475	7,957,216	1,763,882
Gross profit	2,784,912	357,783	4,213,178	422,735
Net income (loss)	4,048,527	213,865	4,669,092	153,719
Total assets	17,227,868	3,518,019	17,227,868	3,518,019
Depreciation	370,404		1,061,569
Interest expense	93,933		199,744
Tax expense
Capital expenditures for long-lived assets	349,898	135,495	1,066,389	1,243,328
Range Water [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net income (loss)	(15,376)		(53,656)
Total assets	14,498		14,498
Depreciation	640		1,066
Interest expense
Tax expense
Capital expenditures for long-lived assets			15,350
Range Security [Member]
Segment Reporting Information [Line Items]
Revenue	156,218		298,393
Cost of services	83,364		159,702
Gross profit	72,854		138,691
Net income (loss)	50,555		71,000
Depreciation	2,891		7,210
Interest expense			224
Tax expense
Capital expenditures for long-lived assets			52,674
Range Land [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net income (loss)
Total assets	1,009,988		1,009,988
Depreciation
Interest expense
Tax expense
Capital expenditures for long-lived assets	976,858		976,858
Drug Development [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net income (loss)	(140,840)	(106,744)	(354,461)	(340,297)
Total assets	11,859	8,334	11,859	8,334
Depreciation
Interest expense
Tax expense
Capital expenditures for long-lived assets
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of services
Gross profit
Net income (loss)	(538,691)	(226,737)	(1,117,898)	(824,198)
Total assets	443,441	681,298	443,441	681,298
Depreciation
Interest expense	41,534		44,133
Tax expense
Capital expenditures for long-lived assets
Stream Mitigation Banking [Member]
Segment Reporting Information [Line Items]
Total assets	$ 136,835		$ 136,835

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Sep. 30, 2023 Segment
Segment Reporting [Abstract]
Number of reportable segments	5

SCHEDULE OF PRO FORMA DATA INFO

SCHEDULE OF PRO FORMA DATA INFORMATION (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Business Acquisition, Pro Forma Revenue	$ 14,388,345	$ 2,186,617
Business Acquisition, Pro Forma Net Income (Loss)	4,455,428	(1,114,280)
Acquired [Member]
Business Acquisition, Pro Forma Revenue
Business Acquisition, Pro Forma Net Income (Loss)
Collins Building [Member]
Business Acquisition, Pro Forma Revenue	1,787,675
Business Acquisition, Pro Forma Net Income (Loss)	2,992,901
Other Companies [Member]
Business Acquisition, Pro Forma Revenue	12,600,670
Business Acquisition, Pro Forma Net Income (Loss)	$ 1,462,527	(1,071,014)
Collins [Member]
Business Acquisition, Pro Forma Revenue		2,186,617
Business Acquisition, Pro Forma Net Income (Loss)		$ (43,266)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - shares	Oct. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Number of shares issued		87,516,815	78,116,814
Purchase Agreement [Member] | Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Number of shares issued	21,733,334
Warrants to purchase	2,173,334